We propose that general inhibitors of inflammation such as NSAIDs or inhibitors of specific pro-inflammatory cytokines such as TNFα and IL-1β—that are constantly present at the tumor site from the time of malignant transformation and onwards—should be considered for the treatment of BC patients. The gene discussed is IL1B; the disease is neoplasm.